Immunocore names AstraZeneca exec as new CEO
Clinical stage biotechnology company Immunocore has announced the appointment of AstraZeneca executive Bahija Jallal as the company’s new CEO.
The privately held, Oxford-based firm is focused on the research and development of biological drugs to treat cancer, infectious diseases and autoimmune diseases using soluble T-cell receptor (TCR) technology.
Bringing to the role more than 25 years’ worth of experience Jallal joins Immunocore from AstraZeneca subsidiary MedImmune, the company’s global biologics research and development arm, where she is president and a member of the senior executive team.
Having authored more than 70 peer-reviewed publications Jallal holds in excess of 15 patents. Under her leadership, MedImmune has seen the development of a number of medicines including cancer drug Imfinzi, having expanded its pipeline from 40 to more than 130 molecules.
Sir John Bell, Chairman of Immunocore, commented: “Bahija is the ideal candidate to lead Immunocore at this transformational point in its development. A champion for science and diversity, Bahija is a highly seasoned pharmaceutical executive with considerable experience in biologics R&D and immuno-oncology. Her appointment will significantly strengthen Immunocore as we advance our lead candidate, IMCgp100, towards commercialisation, and our growing pipeline of TCR candidates through clinical development. I would like to extend my thanks also to Andrew Hotchkiss, who has been a highly capable interim CEO of Immunocore, for his support.”